[Cost-Utility Analysis of Dupilumab for the Treatment of Severe Atopic Dermatitis in Children and Adolescents in Italy]. (2022). Farmeconomia. Health Economics and Therapeutic Pathways, 23(1). https://doi.org/10.7175/fe.v23i1.1527